Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.58
▲ $0.20 (+2.4%)
Market data updated: 09/20 10:05 AM
News analyzed: 09/20/2026
Market Cap
$305.80M
Day Range
$8.37 - $8.71
52-Week Range
$5.16 - $9.32
Beta
—
Next Earnings
—
Support
$5.72
Resistance
$8.72
EPRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+42.1% (1Y)
🟡 Moderate
Strengths: 10/14 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 4.7% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
75
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $8.55
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
1d ago · $8.55
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
Still awaiting outcome
3d ago · $8.09
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
3d ago · $8.09
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
4d ago · $8.11
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
4d ago · $8.11
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
5d ago · $8.22
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
5d ago · $8.22
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
5d ago · $8.22
Evidence: 11 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
5d ago · $8.05
Evidence: -3.7pp vs. sector average today
What happened after
Still awaiting outcome
6d ago · $8.42
Evidence: +5.7pp vs. sector average today
What happened after
Still awaiting outcome
6d ago · $8.42
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
6d ago · $8.42
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
6d ago · $8.42
Evidence: 11 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
7d ago · $8.42
Evidence: +5.5pp vs. sector average today
What happened after
Still awaiting outcome
7d ago · $8.42
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
7d ago · $8.42
Evidence: 1.8x recent average volume
What happened after
Still awaiting outcome
7d ago · $8.42
Evidence: 11 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
9d ago · $8.21
Evidence: +3.6pp vs. sector average today
What happened after
9d ago · $8.21
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 10, 2026
Then
79
$8.08
Now
75
$8.58
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
87
Risk
42
Sentiment
62
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Eupraxia Pharmaceuticals has centered on its **Phase 1b/2a RESOLVE trial** for eosinophilic esophagitis, highlighting significant symptom improvements—such as a **75% reduction in moderate-to-severe odynophagia (painful swallowing)** and **complete elimination of severe cases** after treatment. The company also reported **second-quarter financial results**, including a slight improvement in earnings per share, while reinforcing its leadership team to advance late-stage drug development. Analysts have projected a **145% upside potential** for its stock, reflecting optimism about its pipeline.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Eupraxia Pharmaceuticals Inc.. News trend score: 62. Reason: 5 of the last 18 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
49
🎯 Conviction (vs. Emotion)
50
Psychology
69
Fundamentals
—
Technical
87
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+32%
Market Narrative
72
Fundamental Reality
50
Narrative Gap
+22
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market behavior here is dominated by **anchoring**, as traders fixate on the immediate resistance level (0.0% distance), ignoring broader momentum or peer divergence. The high FOMO (76) and euphoria (46) scores suggest traders are chasing gains, but the narrative gap (15 points) implies optimism may outpace fundamentals. The key question: *Will traders break the resistance anchor, or will the gap between narrative and reality widen?*
Updated: 09/07/2026, 11:48 AM
What could change this?
👥 What the crowd believes
"Reduction of moderate to severe odynophagia from 62% to 25% post-treatment in eosinophilic esophagitis patients"
"Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities"
"Consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc."
"Quarterly losses of $(0.23) per share, inline with analyst estimates"
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Jesse Livermore — 72/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on his documented principles, the model estimates that Livermore and Mackay see a positive trend and crowd excitement, giving scores in the low‑70s and high‑60s, while Howard Marks’ cycle view is moderately favorable. In contrast, classic value and growth frameworks (Graham, Fisher, Lynch, Bagehot, Veblen) all sit at the neutral midpoint of 50 because their methods require balance‑sheet, valuation or growth data that are unavailable for EPRX, leading to a “not enough data” verdict. More risk‑oriented or market‑efficiency lenses—Schwager, Malkiel & Bogle, Loeb, Nelson, Smith, and Housel—assign lower scores, reflecting concerns about weak edge, limited evidence versus an index, heightened capital risk, possible overbought conditions, and volatile price swings. The divergence therefore stems from each methodology’s emphasis: price‑action and crowd sentiment boost the momentum‑focused scores, whereas data‑driven or risk‑averse approaches downgrade the stock due to missing fundamentals and perceived volatility.
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 72
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 53
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 47
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 45
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 32
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 8
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 5 positive, 10 neutral, 3 negative out of the last 18 articles.
Insider Monkey · 12.9.2026
Yahoo · 12.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 2.9.2026
Benzinga · 2.9.2026
GlobeNewswire · 13.8.2026
Yahoo · 13.8.2026
GlobeNewswire · 11.8.2026
Yahoo · 11.8.2026
Benzinga · 11.8.2026
Zacks · 10.8.2026
Yahoo · 10.8.2026
MT Newswires · 28.7.2026
MT Newswires · 13.7.2026
GlobeNewswire · 13.7.2026
GlobeNewswire · 7.7.2026
GlobeNewswire · 19.6.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Eupraxia Pharmaceuticals Inc. (EPRX) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for EPRX specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
EPRX's technical score is 87/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 4.7% of price; %K 94.3 — overbought; Volume is falling despite the price advance — possible weakening.
StockIQ has no recorded dividend payment history for EPRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,112,440 shares short as of 2026-08-31 · vs. 6,043,489 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
38.5% of trading volume this week was short selling, vs. 33.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology